ILMN

$120.84

Market ClosedAs of Mar 17, 8:00 PM UTC

Illumina, Inc.

Intraday

Custom Range:
to
No data available for this range. Intraday data may be limited by the exchange.

Recent News

Investor's Business Daily
Mar 16, 2026

Illumina Stock Sees RS Rating Jump To 82

One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Illumina stock cleared that benchmark Monday, with a jump from 77 to 82 Monday.   Hone Your Stock-Picking Skills By Focusing On These Factors This unique rating measures market leadership by showing how a stock's price movement over the last 52 weeks compares to that of other stocks on the major indexes.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 15, 2026

Assessing Illumina (ILMN) Valuation After Expanded Genomics And Proteomics Alliance With Regeneron

Illumina (ILMN) is back in focus after expanding its Alliance for Genomic Discovery with Regeneron Genetics Center and launching a dataset of more than 50,000 genomes plus proteomic data using Illumina Protein Prep, targeting multiomic drug discovery research. See our latest analysis for Illumina. Despite the latest alliance news, Illumina’s share price at US$118.94 reflects mixed momentum, with a 2.92% 1 day share price return but a 90 day share price return decline of 11.84%. The 1 year...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 15, 2026

Is It Time To Reconsider Illumina (ILMN) After Prolonged Share Price Weakness?

If you are trying to work out whether Illumina is attractively priced or still too expensive, this article walks through the key numbers so you can judge the current share price with more confidence. Illumina's share price closed at US$118.94, with returns of a 4.6% decline over the last 7 days, 1.8% over 30 days, an 11.5% decline year to date, 38.9% over 1 year, a 45.5% decline over 3 years and a 70.6% decline over 5 years. Taken together, these figures give a mixed picture of how the...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 13, 2026

Why Is Viking Therapeutics (VKTX) Up 16.3% Since Last Earnings Report?

Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Zacks
Mar 12, 2026

Exelixis (EXEL) Down 2.8% Since Last Earnings Report: Can It Rebound?

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.